

---

## **Annual General Meeting Date and Director Nomination Closing Date**

---

In accordance with clause 14.3 of the Company's Constitution and ASX Listing Rule 3.13.1, Resonance Health Ltd (ASX: RHT) (**Company**) advises that its next Annual General Meeting will be held on Thursday, 24 November 2022.

The Closing Date for receipt of nominations for the position of Director is 13 October 2022. Any nominations must be received in writing no later than 5:00pm (WST) on this date at the Company's Registered Office.

For further information please contact:

**Nick Allan** – Company Secretary

E: [nicka@resonancehealth.com](mailto:nicka@resonancehealth.com)

P: +61 (0)8 9286 5300

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

### **About Resonance Health**

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high-quality quantitative measurements essential in the management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. A number of these SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan®** - provides an accurate measurement of liver iron concentration (**LIC**) through a non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. FerriScan is internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®** - an AI-driven system for the automated real-time measurement of LIC in patients using non-invasive MRI-based technology.
- **HepaFat-AI®** - an AI-driven system for the automated real-time multi-metric measurement of liver fat in patients using non-invasive MRI-based technology, for use in the assessment of individuals with confirmed or suspected fatty liver disease.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **Alert-PE**, an AI tool for the automated review of chest CT scans of patients with suspected pulmonary embolism.